#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14336	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2490	707.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1614	1614	C	895	C	895	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23600	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3967	740.9	0	.	n	.	0	T695C	SNP	695	695	T	1207	1207	C	868	C,G,A	864,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23600	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3967	740.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1849	1849	A	993	A,C,G	990,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23600	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3967	740.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2483	2483	C	763	C,T,A	759,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23600	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3967	740.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2557	2557	A	654	A	654	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23600	23S	2890	2890	99.9	23S.l6.c17.ctg.1	3967	740.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3109	3109	C	803	C	802	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1976	folP	852	852	100.0	folP.l15.c4.ctg.1	2027	121.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1290	1292	AGC	202;204;207	A;G;C	202;204;207	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4698	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3881	151.1	1	SNP	p	S91F	0	.	.	271	273	TCC	821	823	TCC	171;173;176	T;C;C,A	171;173;175,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4698	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3881	151.1	1	SNP	p	D95N	0	.	.	283	285	GAC	833	835	GAC	183;184;184	G;A,T;C	183;183,1;184	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4698	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3881	151.1	1	SNP	p	D95G	0	.	.	283	285	GAC	833	835	GAC	183;184;184	G;A,T;C	183;183,1;184	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	1690	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1804	116.9	1	SNP	p	G45D	1	.	.	133	135	GAC	692	694	GAC	184;183;184	G;A;C	184;183;184	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1000	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1658	75.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4656	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3501	166.0	1	SNP	p	D86N	0	.	.	256	258	GAC	889	891	GAC	228;226;225	G;A,C;C	228;224,2;225	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4656	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3501	166.0	1	SNP	p	S87R	0	.	.	259	261	AGT	892	894	AGT	223;223;222	A;G;T,A	223;223;221,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4656	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3501	166.0	1	SNP	p	S87I	0	.	.	259	261	AGT	892	894	AGT	223;223;222	A;G;T,A	223;223;221,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4656	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3501	166.0	1	SNP	p	S87W	0	.	.	259	261	AGT	892	894	AGT	223;223;222	A;G;T,A	223;223;221,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4656	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3501	166.0	1	SNP	p	S88P	0	.	.	262	264	TCC	895	897	TCC	221;221;221	T;C;C,A	221;221;220,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3898	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3209	151.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1846	1848	GGC	203;205;204	G;G,C;C	203;204,1;204	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2937	157.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1543	1545	GCA	216;217;215	G,T;C;A	215,1;217;215	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2937	157.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1546	1548	ATC	214;214;214	A;T,G;C	214;213,1;214	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2937	157.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1558	1560	GTG	216;217;216	G;T,G;G,T	216;216,1;215,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2937	157.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1558	1560	GTG	216;217;216	G;T,G;G,T	216;216,1;215,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2937	157.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2062	2064	ACC	189;191;193	A,T;C;C	188,1;191;193	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2937	157.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2116	2118	GCG	182;183;184	G;C;G	182;183;184	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2937	157.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2116	2118	GCG	182;183;184	G;C;G	182;183;184	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2937	157.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2239	2241	GGC	224;224;220	G;G,C;C,T	224;223,1;219,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2937	157.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2248	2250	GGC	220;220;219	G;G,C;C	220;219,1;219	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3708	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2937	157.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2266	2268	CCG	227;227;222	C,G;C,A;G	226,1;226,1;222	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5230	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3690	176.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2268	porA	1146	1146	99.83	porA.l6.c17.ctg.1	2239	126.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	753	753	C	157	C,T	156,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	S271T	NONSYN	811	813	TCG	127	129	ACT	69;69;69	A;C;T	69;69;69	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	133	135	GAT	69;69;69	G;A;T	69;69;69	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	D274S	NONSYN	820	822	GAT	136	138	AGT	69;69;69	A;G;T,G	69;69;68,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	N277H	NONSYN	829	831	AAC	145	147	CAC	69;69;69	C;A;C	69;69;69	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	R307E	NONSYN	919	921	AGA	235	237	GAA	5;5;5	G;A;A	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	T311A	NONSYN	931	933	ACA	247	249	GCA	5;5;5	G;C;A	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	E312D	NONSYN	934	936	GAA	250	252	GAC	5;5;5	G;A;C	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	F314I	NONSYN	940	942	TTC	256	258	ATC	5;5;5	A;T;C	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	A316S	NONSYN	946	948	GCG	262	264	TCG	5;5;5	T;C;G	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	V318A	NONSYN	952	954	GTC	268	270	GCC	5;5;5	G;C;C	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	G319S	NONSYN	955	957	GGC	271	273	AGC	5;5;5	A;G;C	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	G320A	NONSYN	958	960	GGT	274	276	GCC	5;5;5	G;C;C	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	316	porB1a	984	271	91.51	porB1a.l15.c30.ctg.2	408	27.9	0	.	p	.	0	G322V	NONSYN	964	966	GGT	280	282	GTT	4;4;4	G;T;T	4;4;4	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	R40Q	NONSYN	118	120	CGG	565	567	CAG	239;239;236	C,G;A;G	238,1;239;236	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	589	591	GGA	234;235;234	G;G;A	234;235;234	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	T87A	NONSYN	259	261	ACT	706	708	GCT	199;200;199	G,T;C;T	198,1;200;199	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	T89S	NONSYN	265	267	ACC	712	714	AGC	193;194;195	A;G,C;C	193;193,1;195	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	.	MULTIPLE	358	359	AA	804	805	CG	210;209	C;G	210;209	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	.	MULTIPLE	361	362	GA	807	809	CAG	207;213;213	C;A;G	207;213;213	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	N122K	NONSYN	364	366	AAC	811	813	AAA	211;211;211	A,G,C;A;A	209,1,1;211;211	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	K143E	NONSYN	427	429	AAA	874	876	GAA	228;231;230	G;A;A	228;231;230	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	V151A	NONSYN	451	453	GTA	898	900	GCA	243;243;242	G;C;A,G	243;243;241,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	N212D	NONSYN	634	636	AAT	1081	1083	GAT	205;203;205	G,T;A,C;T	204,1;202,1;205	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	D213G	NONSYN	637	639	GAT	1084	1086	GGT	205;204;202	G;G;T	205;204;202	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1099	1101	ATG	193;196;189	A;T;G	193;196;189	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1213	1215	GCA	191;192;194	G;C,A;A	191;191,1;194	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1216	1218	ACG	192;196;197	A;C;G	192;196;197	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	R258G	NONSYN	772	774	CGT	1219	1221	GGG	196;197;197	G;G,C;G,T	196;196,1;196,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1222	1224	GTT	197;199;199	G,T;T,G;T	196,1;197,2;199	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1282	1284	GTA	204;204;205	G;T;A	204;204;205	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1321	1323	ACT	220;219;219	A;C;T	220;219;219	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1327	1329	GAT	227;228;229	G,A;A;T	226,1;228;229	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1339	1341	CAC	237;236;240	C,T;A;C	236,1;236;240	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	1	SNP	p	G120K	1	.	.	358	360	AAG	804	806	CGG	210;209;209	C;G;G,A	210;209;208,1	porB1b.WHO_Z_02266c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	1	SNP	p	A121D	1	.	.	361	363	GAC	807	810	CGC	207;213;212	C;G;C,G	207;213;211,1	porB1b.WHO_Z_02266c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2612	porB1b	1047	1047	97.04	porB1b.l15.c17.ctg.1	1653	194.4	1	SNP	p	D121N	0	.	.	361	363	GAC	807	810	CGC	207;213;212	C;G;C,G	207;213;211,1	porB1b.WHO_Z_02266c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9232	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5406	213.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2239	2241	AAT	234;235;237	A;A;T	234;235;237	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1432	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1493	119.7	1	SNP	p	V57M	1	.	.	169	171	ATG	726	728	ATG	268;264;261	A;T;G,A	268;264;260,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
